Overall: * Negative EPS * June 7th conference @Asco will most likely lead to a double-top. * The "surge" is starting to end, if not has already ended. Share price should return to anywhere between $8-11, possibly even lower. * Medical breakthroughs, as a whole, when it comes to cancers, which this company focuses on, are slow, unlikely, and uncommon. And I suspect, the share price will not be Mooning, anytime soon.